PARP1 and cancer: Currently, four PARP inhibitors including Olaparib, Rucaparib, Niraparib, and Talazoparib have been authorized by the U.S. Food and Drug Administration (FDA) (Kim et al., 2021), which are all used for the treatment of cancers.